司美替尼联合MK-2206对比奥沙利铂联合氟尿嘧啶在经治转移性胰腺癌患者中的疗效:SWOG S1115随机临床试验
SWOG S1115是一项随机2期临床试验,纳入137例吉西他滨治疗失败的转移性胰腺腺癌患者,1:1随机接受司美替尼联合MK-2206或mFOLFOX方案治疗。结果显示,试验组中位总生存期(3.9 vs 6.7个月;HR 1.37;95%CI 0.90-2.08;P=0.15)和中位无进展生存期(1.9 vs 2.0个月;HR 1.61;95%CI 1.07-2.43;P=0.02)均未优于mFOLFOX组。
要点
- 司美替尼联合MK-2206未改善吉西他滨失败后转移性胰腺癌患者的总生存期。
- 试验组中位无进展生存期较mFOLFOX组缩短(1.9 vs 2.0个月;HR 1.61;95%CI 1.07-2.43;P=0.02)。
- 试验组3级及以上毒性反应及因不良事件停药的患者数均多于mFOLFOX组。
核心结论
- 司美替尼联合MK-2206双重阻断KRAS下游的MEK和PI3K/AKT通路,未能改善吉西他滨治疗失败的转移性胰腺腺癌患者的总生存期。
研究设计与样本
- SWOG S1115是一项随机2期临床试验,于2012年9月至2014年5月纳入137例吉西他滨治疗失败的转移性胰腺腺癌患者,按1:1随机分组并按既往系统治疗时长和肝转移 presence 分层。
主要发现
- 试验组(司美替尼联合MK-2206)58例,mFOLFOX组62例;试验组中位总生存期较短(3.9 vs 6.7个月;HR 1.37;95%CI 0.90-2.08;P=0.15)。
- 试验组中位无进展生存期较短(1.9 vs 2.0个月;HR 1.61;95%CI 1.07-2.43;P=0.02)。
- 试验组 vs mFOLFOX组:部分缓解1例 vs 5例,疾病稳定12例 vs 14例。
- 3级及以上毒性反应:试验组39例 vs mFOLFOX组23例;因不良事件停药:试验组13例 vs mFOLFOX组7例。
关键数值与推荐
- 试验组给药方案:司美替尼100 mg口服每日一次,联合MK-2206 135 mg口服每周一次。
- mFOLFOX组给药方案:奥沙利铂85 mg/m2静脉给药,氟尿嘧啶2400 mg/m2静脉输注46-48小时,于28天周期的第1天和第15天给药。
临床怎么用
- 作者结论认为,司美替尼联合MK-2206未改善吉西他滨治疗失败的转移性胰腺腺癌患者的总生存期。
- 作者指出,这是美国人群中首次对mFOLFOX进行的随机前瞻性评估,其结果与CONKO-003和PANCREOX相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolong survival. This was the first cooperative group trial to evaluate this strategy using molecularly targeted oral combination therapy for the treatment of chemotherapy-refractory pancreatic cancer. OBJECTIVE: To compare selumetinib and MK-2206 vs modified FOLFOX (mFOLFOX) in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed. DESIGN, SETTING, AND PARTICIPANTS: SWOG S1115 was a randomized phase 2 clinical trial. Between September 2012 and May 2014, 137 patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy had failed were randomized to selumetinib plus MK-2206 or mFOLFOX. Patients were randomized in a 1:1 fashion and stratified according to duration of prior systemic therapy and presence of liver metastases. INTERVENTIONS: Patients received selumetinib 100 mg orally per day plus MK-2206 135 mg orally once per week or mFOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15 of a 28-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point of the study was overall survival. Secondary objectives included evaluating toxic effects, objective tumor response, and progression-free survival. RESULTS: There were 58 patients in the selumetinib plus MK-2206 (experimental) arm (60% male; median [range] age, 69 [54-88] years) and 62 patients in the mFOLFOX arm (35% male; median [range] age, 65 [34-82] years). In the experimental arm, median overall survival was shorter (3.9 vs 6.7 months; HR, 1.37; 95% CI, 0.90-2.08; P = .15), as was median progression-free survival (1.9 vs 2.0 months; HR, 1.61; 95% CI, 1.07-2.43; P = .02). One vs 5 patients had a partial response and 12 vs 14 patients had stable disease in the experimental arm vs mFOLFOX arm. Grade 3 or higher toxic effects were observed in 39 patients treated with selumetinib and MK-2206 vs 23 patients treated with mFOLFOX. More patients in the experimental arm discontinued therapy due to adverse events (13 vs 7 patients). CONCLUSIONS AND RELEVANCE: Dual targeting of the MEK and PI3K/AKT pathways downstream of KRAS by selumetinib plus MK-2206 did not improve overall survival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy had failed. This was the first randomized prospective evaluation of mFOLFOX in the US population that showed comparable results to CONKO-003 and PANCREOX. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01658943.
引用
- Chung V, McDonough S, Philip PA, et al. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 27978579. doi:10.1001/jamaoncol.2016.5383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。